Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSTR Imaging in ER+ Metastatic Breast Cancer
NCT05880394Phase 2Active, not recruiting
- Sponsor
- Hoag Memorial Hospital Presbyterian
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga 68 dotatate and copper Cu 64 dotatate in breast cancer, sponsored by Hoag Memorial Hospital Presbyterian. Primary endpoint: Uptake of Ga-68-DOTATATE or Copper-64 DOTATATE at 6 months. Started Jan 2023; status: active, not recruiting.
02
Drugs
gallium ga 68 dotatatecopper Cu 64 dotatate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05880394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05880394.